IC
RLMD icon

Ikarian Capital’s Relmada Therapeutics RLMD Stock Holding History

Ikarian Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-775,300
Closed -$28.7M – 103
2022
Q3 		$28.7M Buy
775,300
+493,000
+175% +$13.7M 5.72% 1
2022
Q2 		$5.36M Buy
+282,300
New +$6.16M 0.98% 34

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital's RLMD Position: Q2 2026 in Review

Ikarian Capital reduced its Relmada Therapeutics (RLMD) stake by 20% in Q2 2026, selling an estimated $3.77M and leaving 2,148,359 shares worth $14.9M. The position accounts for 1.6% of the portfolio, ranked #15.

Ikarian Capital first reported a position in RLMD in Q1 2020 and has held it in 21 quarters since. The position peaked at $18.7M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Ikarian Capital held 2,148,359 shares of Relmada Therapeutics worth $14.9M as of Q2 2026.
  • Ikarian Capital sold 540,000 Relmada Therapeutics shares in Q2 2026, an estimated $3.77M.
  • Relmada Therapeutics made up 1.6% of Ikarian Capital's portfolio in Q2 2026, its #15 holding.
  • Ikarian Capital first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Ikarian Capital's Relmada Therapeutics position peaked at $18.7M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.